Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11

Frias J, Bonora E, Cox D, Kwan A, Raha S, Bethel A, Malik R

Journal of the Endocrine Society3 May 2021

PMCIDPMC8090394PepBankPUB-90678124

Read at source Source pageAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study28

27 results from studies that gave the peptide. 27 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dulaglutide maintained A1C reductions across baseline categories at 52 weeks, ranging from -1.0 to -2.1%.
In plain wordsDulaglutide maintained lower A1C than baseline across initial A1C categories in patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1C change across subgroups at 52 weeks
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · 52 weeksAs given in this study (human).
Measurements
A1C change from baseline range across baseline A1C categories
−1 to −2.1%
dulaglutide 1.5 mg, 52 weeks
Source sentences
Summary
DU 1.5 mg reduced A1C across all baseline A1C categories at 36 weeks (range, -1.0 to -2.2%) and effects were sustained through 52 weeks (range, -1.0 to -2.1%).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812402
02HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C below 8%, dulaglutide 1.5 mg reduced A1C by 1.0%.
In plain wordsIn patients with initial A1C below 8%, dulaglutide 1.5 mg lowered A1C from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1C change with baseline below 8%
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
A1C change from baseline (least-squares mean)
−1%
dulaglutide 1.5 mg, baseline A1C <8%, 36 weeks
Source sentences
Summary
A1C subgroup, least-squares mean change in A1C [%] with 1.5 mg, 3 mg, and 4.5 mg, respectively: A1C<8%, -1.0, -1.2, -1.2;
3 context sentences(design, population, supporting numbers)
Summary · context
A1C reductions were greater in patients randomized to DU 3 mg or 4.5 mg versus 1.5 mg in each A1C subgroup, with greater dose-related improvements in patients with higher baseline A1C through 36 weeks
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812403
03HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C below 8%, A1C fell by 1.2% with dulaglutide 3 mg versus 1.0% with 1.5 mg.
In plain wordsIn patients with initial A1C below 8%, dulaglutide 3 mg lowered A1C more than 1.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1C change with baseline below 8%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg weekly · 36 weeksAs given in this study (human).
Measurements
A1C change from baseline (least-squares mean)
−1.2%
dulaglutide 3 mg, baseline A1C <8%, 36 weeks
A1C change from baseline (least-squares mean)
−1%
dulaglutide 1.5 mg, baseline A1C <8%, 36 weeks
Source sentences
Summary
A1C subgroup, least-squares mean change in A1C [%] with 1.5 mg, 3 mg, and 4.5 mg, respectively: A1C<8%, -1.0, -1.2, -1.2;
3 context sentences(design, population, supporting numbers)
Summary · context
A1C reductions were greater in patients randomized to DU 3 mg or 4.5 mg versus 1.5 mg in each A1C subgroup, with greater dose-related improvements in patients with higher baseline A1C through 36 weeks
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812404
04HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C below 8%, A1C fell by 1.2% with dulaglutide 4.5 mg versus 1.0% with 1.5 mg.
In plain wordsIn patients with initial A1C below 8%, dulaglutide 4.5 mg lowered A1C more than 1.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1C change with baseline below 8%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
A1C change from baseline (least-squares mean)
−1.2%
dulaglutide 4.5 mg, baseline A1C <8%, 36 weeks
A1C change from baseline (least-squares mean)
−1%
dulaglutide 1.5 mg, baseline A1C <8%, 36 weeks
Source sentences
Summary
A1C subgroup, least-squares mean change in A1C [%] with 1.5 mg, 3 mg, and 4.5 mg, respectively: A1C<8%, -1.0, -1.2, -1.2;
3 context sentences(design, population, supporting numbers)
Summary · context
A1C reductions were greater in patients randomized to DU 3 mg or 4.5 mg versus 1.5 mg in each A1C subgroup, with greater dose-related improvements in patients with higher baseline A1C through 36 weeks
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812405
05HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C 8 to below 9%, dulaglutide 1.5 mg reduced A1C by 1.4%.
In plain wordsDulaglutide 1.5 mg lowered A1C from baseline in patients with initial A1C 8 to below 9%.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1C change with baseline 8 to below 9%
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
A1C change from baseline (least-squares mean)
−1.4%
dulaglutide 1.5 mg, baseline A1C 8-<9%, 36 weeks
Source sentences
Summary
A1C subgroup, least-squares mean change in A1C [%] with 1.5 mg, 3 mg, and 4.5 mg, respectively: A1C<8%, -1.0, -1.2, -1.2; A1C 8-<9%, -1.4, -1.6, -1.8;
3 context sentences(design, population, supporting numbers)
Summary · context
A1C reductions were greater in patients randomized to DU 3 mg or 4.5 mg versus 1.5 mg in each A1C subgroup, with greater dose-related improvements in patients with higher baseline A1C through 36 weeks
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812406
06HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C 8 to below 9%, A1C fell by 1.6% with dulaglutide 3 mg versus 1.4% with 1.5 mg.
In plain wordsDulaglutide 3 mg lowered A1C more than 1.5 mg in patients with initial A1C 8 to below 9%.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1C change with baseline 8 to below 9%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg weekly · 36 weeksAs given in this study (human).
Measurements
A1C change from baseline (least-squares mean)
−1.6%
dulaglutide 3 mg, baseline A1C 8-<9%, 36 weeks
A1C change from baseline (least-squares mean)
−1.4%
dulaglutide 1.5 mg, baseline A1C 8-<9%, 36 weeks
Source sentences
Summary
A1C subgroup, least-squares mean change in A1C [%] with 1.5 mg, 3 mg, and 4.5 mg, respectively: A1C<8%, -1.0, -1.2, -1.2; A1C 8-<9%, -1.4, -1.6, -1.8;
3 context sentences(design, population, supporting numbers)
Summary · context
A1C reductions were greater in patients randomized to DU 3 mg or 4.5 mg versus 1.5 mg in each A1C subgroup, with greater dose-related improvements in patients with higher baseline A1C through 36 weeks
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812407
07HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C 8 to below 9%, A1C fell by 1.8% with dulaglutide 4.5 mg versus 1.4% with 1.5 mg.
In plain wordsDulaglutide 4.5 mg lowered A1C more than 1.5 mg in patients with initial A1C 8 to below 9%.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1C change with baseline 8 to below 9%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
A1C change from baseline (least-squares mean)
−1.8%
dulaglutide 4.5 mg, baseline A1C 8-<9%, 36 weeks
A1C change from baseline (least-squares mean)
−1.4%
dulaglutide 1.5 mg, baseline A1C 8-<9%, 36 weeks
Source sentences
Summary
A1C subgroup, least-squares mean change in A1C [%] with 1.5 mg, 3 mg, and 4.5 mg, respectively: A1C<8%, -1.0, -1.2, -1.2; A1C 8-<9%, -1.4, -1.6, -1.8;
3 context sentences(design, population, supporting numbers)
Summary · context
A1C reductions were greater in patients randomized to DU 3 mg or 4.5 mg versus 1.5 mg in each A1C subgroup, with greater dose-related improvements in patients with higher baseline A1C through 36 weeks
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812408
08HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C 9 to below 10%, dulaglutide 1.5 mg reduced A1C by 2.1%.
In plain wordsDulaglutide 1.5 mg lowered A1C from baseline in patients with initial A1C 9 to below 10%.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1C change with baseline 9 to below 10%
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
A1C change from baseline (least-squares mean)
−2.1%
dulaglutide 1.5 mg, baseline A1C 9-<10%, 36 weeks
Source sentences
Summary
A1C subgroup, least-squares mean change in A1C [%] with 1.5 mg, 3 mg, and 4.5 mg, respectively: A1C<8%, -1.0, -1.2, -1.2; A1C 8-<9%, -1.4, -1.6, -1.8; A1C 9-<10%, -2.1, -2.2, -2.3;
3 context sentences(design, population, supporting numbers)
Summary · context
A1C reductions were greater in patients randomized to DU 3 mg or 4.5 mg versus 1.5 mg in each A1C subgroup, with greater dose-related improvements in patients with higher baseline A1C through 36 weeks
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812409
09HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C 9 to below 10%, A1C fell by 2.2% with dulaglutide 3 mg versus 2.1% with 1.5 mg.
In plain wordsDulaglutide 3 mg lowered A1C more than 1.5 mg in patients with initial A1C 9 to below 10%.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1C change with baseline 9 to below 10%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg weekly · 36 weeksAs given in this study (human).
Measurements
A1C change from baseline (least-squares mean)
−2.2%
dulaglutide 3 mg, baseline A1C 9-<10%, 36 weeks
A1C change from baseline (least-squares mean)
−2.1%
dulaglutide 1.5 mg, baseline A1C 9-<10%, 36 weeks
Source sentences
Summary
A1C subgroup, least-squares mean change in A1C [%] with 1.5 mg, 3 mg, and 4.5 mg, respectively: A1C<8%, -1.0, -1.2, -1.2; A1C 8-<9%, -1.4, -1.6, -1.8; A1C 9-<10%, -2.1, -2.2, -2.3;
3 context sentences(design, population, supporting numbers)
Summary · context
A1C reductions were greater in patients randomized to DU 3 mg or 4.5 mg versus 1.5 mg in each A1C subgroup, with greater dose-related improvements in patients with higher baseline A1C through 36 weeks
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812410
10HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C 9 to below 10%, A1C fell by 2.3% with dulaglutide 4.5 mg versus 2.1% with 1.5 mg.
In plain wordsDulaglutide 4.5 mg lowered A1C more than 1.5 mg in patients with initial A1C 9 to below 10%.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1C change with baseline 9 to below 10%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
A1C change from baseline (least-squares mean)
−2.3%
dulaglutide 4.5 mg, baseline A1C 9-<10%, 36 weeks
A1C change from baseline (least-squares mean)
−2.1%
dulaglutide 1.5 mg, baseline A1C 9-<10%, 36 weeks
Source sentences
Summary
A1C subgroup, least-squares mean change in A1C [%] with 1.5 mg, 3 mg, and 4.5 mg, respectively: A1C<8%, -1.0, -1.2, -1.2; A1C 8-<9%, -1.4, -1.6, -1.8; A1C 9-<10%, -2.1, -2.2, -2.3;
3 context sentences(design, population, supporting numbers)
Summary · context
A1C reductions were greater in patients randomized to DU 3 mg or 4.5 mg versus 1.5 mg in each A1C subgroup, with greater dose-related improvements in patients with higher baseline A1C through 36 weeks
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812411
11HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C at least 10%, dulaglutide 1.5 mg reduced A1C by 2.2%.
In plain wordsDulaglutide 1.5 mg lowered A1C from baseline in patients with initial A1C at least 10%.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1C change with baseline at least 10%
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
A1C change from baseline (least-squares mean)
−2.2%
dulaglutide 1.5 mg, baseline A1C ≥10%, 36 weeks
Source sentences
Summary
A1C subgroup, least-squares mean change in A1C [%] with 1.5 mg, 3 mg, and 4.5 mg, respectively: A1C<8%, -1.0, -1.2, -1.2; A1C 8-<9%, -1.4, -1.6, -1.8; A1C 9-<10%, -2.1, -2.2, -2.3; A1C ≥10%, -2.2, -2.5, -3.2; interaction p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
A1C reductions were greater in patients randomized to DU 3 mg or 4.5 mg versus 1.5 mg in each A1C subgroup, with greater dose-related improvements in patients with higher baseline A1C through 36 weeks
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812412
12HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C at least 10%, A1C fell by 2.5% with dulaglutide 3 mg versus 2.2% with 1.5 mg.
In plain wordsDulaglutide 3 mg lowered A1C more than 1.5 mg in patients with initial A1C at least 10%.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1C change with baseline at least 10%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg weekly · 36 weeksAs given in this study (human).
Measurements
A1C change from baseline (least-squares mean)
−2.5%
dulaglutide 3 mg, baseline A1C ≥10%, 36 weeks
A1C change from baseline (least-squares mean)
−2.2%
dulaglutide 1.5 mg, baseline A1C ≥10%, 36 weeks
Source sentences
Summary
A1C subgroup, least-squares mean change in A1C [%] with 1.5 mg, 3 mg, and 4.5 mg, respectively: A1C<8%, -1.0, -1.2, -1.2; A1C 8-<9%, -1.4, -1.6, -1.8; A1C 9-<10%, -2.1, -2.2, -2.3; A1C ≥10%, -2.2, -2.5, -3.2; interaction p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
A1C reductions were greater in patients randomized to DU 3 mg or 4.5 mg versus 1.5 mg in each A1C subgroup, with greater dose-related improvements in patients with higher baseline A1C through 36 weeks
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812413
13HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C at least 10%, A1C fell by 3.2% with dulaglutide 4.5 mg versus 2.2% with 1.5 mg.
In plain wordsDulaglutide 4.5 mg lowered A1C more than 1.5 mg in patients with initial A1C at least 10%.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1C change with baseline at least 10%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
A1C change from baseline (least-squares mean)
−3.2%
dulaglutide 4.5 mg, baseline A1C ≥10%, 36 weeks
A1C change from baseline (least-squares mean)
−2.2%
dulaglutide 1.5 mg, baseline A1C ≥10%, 36 weeks
Source sentences
Summary
A1C subgroup, least-squares mean change in A1C [%] with 1.5 mg, 3 mg, and 4.5 mg, respectively: A1C<8%, -1.0, -1.2, -1.2; A1C 8-<9%, -1.4, -1.6, -1.8; A1C 9-<10%, -2.1, -2.2, -2.3; A1C ≥10%, -2.2, -2.5, -3.2; interaction p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
A1C reductions were greater in patients randomized to DU 3 mg or 4.5 mg versus 1.5 mg in each A1C subgroup, with greater dose-related improvements in patients with higher baseline A1C through 36 weeks
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812414
14HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C below 8%, 75% reached A1C below 7% with dulaglutide 1.5 mg.
In plain wordsWith dulaglutide 1.5 mg, 75% of patients with initial A1C below 8% reached A1C below 7%.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableA1C target with baseline below 8%
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
Patients achieving A1C <7%
75%
dulaglutide 1.5 mg, baseline A1C <8%, 36 weeks
Source sentences
Summary
Over half of patients randomized to DU 4.5 mg achieved A1C <7% in every baseline A1C category (A1C<8%, 75%, 87%, 83%; A1C 8-<9%, 61%, 64%, 73%; A1C 9-<10%, 46%, 51%, 64%; A1C ≥10%, 19%, 33%, 55% for DU 1.5 mg, 3 mg, and 4.5 mg, respectively; interaction p=0.096).
3 context sentences(design, population, supporting numbers)
Summary · context
More patients randomized to 3 mg or 4.5 mg achieved A1C <7% versus those on 1.5 mg at 36 weeks regardless of baseline A1C, but the difference across dose groups was greater at higher baseline A1Cs.
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812415
15HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C 8 to below 9%, 61% reached A1C below 7% with dulaglutide 1.5 mg.
In plain wordsWith dulaglutide 1.5 mg, 61% of patients with initial A1C 8 to below 9% reached A1C below 7%.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableA1C target with baseline 8 to below 9%
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
Patients achieving A1C <7%
61%
dulaglutide 1.5 mg, baseline A1C 8-<9%, 36 weeks
Source sentences
Summary
Over half of patients randomized to DU 4.5 mg achieved A1C <7% in every baseline A1C category (A1C<8%, 75%, 87%, 83%; A1C 8-<9%, 61%, 64%, 73%; A1C 9-<10%, 46%, 51%, 64%; A1C ≥10%, 19%, 33%, 55% for DU 1.5 mg, 3 mg, and 4.5 mg, respectively; interaction p=0.096).
3 context sentences(design, population, supporting numbers)
Summary · context
More patients randomized to 3 mg or 4.5 mg achieved A1C <7% versus those on 1.5 mg at 36 weeks regardless of baseline A1C, but the difference across dose groups was greater at higher baseline A1Cs.
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812416
16HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C 9 to below 10%, 46% reached A1C below 7% with dulaglutide 1.5 mg.
In plain wordsWith dulaglutide 1.5 mg, 46% of patients with initial A1C 9 to below 10% reached A1C below 7%.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableA1C target with baseline 9 to below 10%
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
Patients achieving A1C <7%
46%
dulaglutide 1.5 mg, baseline A1C 9-<10%, 36 weeks
Source sentences
Summary
Over half of patients randomized to DU 4.5 mg achieved A1C <7% in every baseline A1C category (A1C<8%, 75%, 87%, 83%; A1C 8-<9%, 61%, 64%, 73%; A1C 9-<10%, 46%, 51%, 64%; A1C ≥10%, 19%, 33%, 55% for DU 1.5 mg, 3 mg, and 4.5 mg, respectively; interaction p=0.096).
3 context sentences(design, population, supporting numbers)
Summary · context
More patients randomized to 3 mg or 4.5 mg achieved A1C <7% versus those on 1.5 mg at 36 weeks regardless of baseline A1C, but the difference across dose groups was greater at higher baseline A1Cs.
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812417
17HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C at least 10%, 19% reached A1C below 7% with dulaglutide 1.5 mg.
In plain wordsWith dulaglutide 1.5 mg, 19% of patients with initial A1C at least 10% reached A1C below 7%.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableA1C target with baseline at least 10%
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
Patients achieving A1C <7%
19%
dulaglutide 1.5 mg, baseline A1C ≥10%, 36 weeks
Source sentences
Summary
Over half of patients randomized to DU 4.5 mg achieved A1C <7% in every baseline A1C category (A1C<8%, 75%, 87%, 83%; A1C 8-<9%, 61%, 64%, 73%; A1C 9-<10%, 46%, 51%, 64%; A1C ≥10%, 19%, 33%, 55% for DU 1.5 mg, 3 mg, and 4.5 mg, respectively; interaction p=0.096).
3 context sentences(design, population, supporting numbers)
Summary · context
More patients randomized to 3 mg or 4.5 mg achieved A1C <7% versus those on 1.5 mg at 36 weeks regardless of baseline A1C, but the difference across dose groups was greater at higher baseline A1Cs.
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812418
18HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C below 8%, 87% reached A1C below 7% with dulaglutide 3 mg versus 75% with 1.5 mg.
In plain wordsMore patients with initial A1C below 8% reached A1C below 7% with dulaglutide 3 mg than with 1.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseA1C target with baseline below 8%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg weekly · 36 weeksAs given in this study (human).
Measurements
Patients achieving A1C <7%
87%
dulaglutide 3 mg, baseline A1C <8%, 36 weeks
Patients achieving A1C <7%
75%
dulaglutide 1.5 mg, baseline A1C <8%, 36 weeks
Source sentences
Summary
Over half of patients randomized to DU 4.5 mg achieved A1C <7% in every baseline A1C category (A1C<8%, 75%, 87%, 83%; A1C 8-<9%, 61%, 64%, 73%; A1C 9-<10%, 46%, 51%, 64%; A1C ≥10%, 19%, 33%, 55% for DU 1.5 mg, 3 mg, and 4.5 mg, respectively; interaction p=0.096).
3 context sentences(design, population, supporting numbers)
Summary · context
More patients randomized to 3 mg or 4.5 mg achieved A1C <7% versus those on 1.5 mg at 36 weeks regardless of baseline A1C, but the difference across dose groups was greater at higher baseline A1Cs.
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812419
19HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C 8 to below 9%, 64% reached A1C below 7% with dulaglutide 3 mg versus 61% with 1.5 mg.
In plain wordsMore patients with initial A1C 8 to below 9% reached A1C below 7% with dulaglutide 3 mg than with 1.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseA1C target with baseline 8 to below 9%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg weekly · 36 weeksAs given in this study (human).
Measurements
Patients achieving A1C <7%
64%
dulaglutide 3 mg, baseline A1C 8-<9%, 36 weeks
Patients achieving A1C <7%
61%
dulaglutide 1.5 mg, baseline A1C 8-<9%, 36 weeks
Source sentences
Summary
Over half of patients randomized to DU 4.5 mg achieved A1C <7% in every baseline A1C category (A1C<8%, 75%, 87%, 83%; A1C 8-<9%, 61%, 64%, 73%; A1C 9-<10%, 46%, 51%, 64%; A1C ≥10%, 19%, 33%, 55% for DU 1.5 mg, 3 mg, and 4.5 mg, respectively; interaction p=0.096).
3 context sentences(design, population, supporting numbers)
Summary · context
More patients randomized to 3 mg or 4.5 mg achieved A1C <7% versus those on 1.5 mg at 36 weeks regardless of baseline A1C, but the difference across dose groups was greater at higher baseline A1Cs.
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812420
20HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C 9 to below 10%, 51% reached A1C below 7% with dulaglutide 3 mg versus 46% with 1.5 mg.
In plain wordsMore patients with initial A1C 9 to below 10% reached A1C below 7% with dulaglutide 3 mg than with 1.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseA1C target with baseline 9 to below 10%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg weekly · 36 weeksAs given in this study (human).
Measurements
Patients achieving A1C <7%
51%
dulaglutide 3 mg, baseline A1C 9-<10%, 36 weeks
Patients achieving A1C <7%
46%
dulaglutide 1.5 mg, baseline A1C 9-<10%, 36 weeks
Source sentences
Summary
Over half of patients randomized to DU 4.5 mg achieved A1C <7% in every baseline A1C category (A1C<8%, 75%, 87%, 83%; A1C 8-<9%, 61%, 64%, 73%; A1C 9-<10%, 46%, 51%, 64%; A1C ≥10%, 19%, 33%, 55% for DU 1.5 mg, 3 mg, and 4.5 mg, respectively; interaction p=0.096).
3 context sentences(design, population, supporting numbers)
Summary · context
More patients randomized to 3 mg or 4.5 mg achieved A1C <7% versus those on 1.5 mg at 36 weeks regardless of baseline A1C, but the difference across dose groups was greater at higher baseline A1Cs.
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812421
21HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C at least 10%, 33% reached A1C below 7% with dulaglutide 3 mg versus 19% with 1.5 mg.
In plain wordsMore patients with initial A1C at least 10% reached A1C below 7% with dulaglutide 3 mg than with 1.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseA1C target with baseline at least 10%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg weekly · 36 weeksAs given in this study (human).
Measurements
Patients achieving A1C <7%
33%
dulaglutide 3 mg, baseline A1C ≥10%, 36 weeks
Patients achieving A1C <7%
19%
dulaglutide 1.5 mg, baseline A1C ≥10%, 36 weeks
Source sentences
Summary
Over half of patients randomized to DU 4.5 mg achieved A1C <7% in every baseline A1C category (A1C<8%, 75%, 87%, 83%; A1C 8-<9%, 61%, 64%, 73%; A1C 9-<10%, 46%, 51%, 64%; A1C ≥10%, 19%, 33%, 55% for DU 1.5 mg, 3 mg, and 4.5 mg, respectively; interaction p=0.096).
3 context sentences(design, population, supporting numbers)
Summary · context
More patients randomized to 3 mg or 4.5 mg achieved A1C <7% versus those on 1.5 mg at 36 weeks regardless of baseline A1C, but the difference across dose groups was greater at higher baseline A1Cs.
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812422
22HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C below 8%, 83% reached A1C below 7% with dulaglutide 4.5 mg versus 75% with 1.5 mg.
In plain wordsMore patients with initial A1C below 8% reached A1C below 7% with dulaglutide 4.5 mg than with 1.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseA1C target with baseline below 8%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
Patients achieving A1C <7%
83%
dulaglutide 4.5 mg, baseline A1C <8%, 36 weeks
Patients achieving A1C <7%
75%
dulaglutide 1.5 mg, baseline A1C <8%, 36 weeks
Source sentences
Summary
Over half of patients randomized to DU 4.5 mg achieved A1C <7% in every baseline A1C category (A1C<8%, 75%, 87%, 83%; A1C 8-<9%, 61%, 64%, 73%; A1C 9-<10%, 46%, 51%, 64%; A1C ≥10%, 19%, 33%, 55% for DU 1.5 mg, 3 mg, and 4.5 mg, respectively; interaction p=0.096).
3 context sentences(design, population, supporting numbers)
Summary · context
More patients randomized to 3 mg or 4.5 mg achieved A1C <7% versus those on 1.5 mg at 36 weeks regardless of baseline A1C, but the difference across dose groups was greater at higher baseline A1Cs.
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812423
23HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C 8 to below 9%, 73% reached A1C below 7% with dulaglutide 4.5 mg versus 61% with 1.5 mg.
In plain wordsMore patients with initial A1C 8 to below 9% reached A1C below 7% with dulaglutide 4.5 mg than with 1.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseA1C target with baseline 8 to below 9%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
Patients achieving A1C <7%
73%
dulaglutide 4.5 mg, baseline A1C 8-<9%, 36 weeks
Patients achieving A1C <7%
61%
dulaglutide 1.5 mg, baseline A1C 8-<9%, 36 weeks
Source sentences
Summary
Over half of patients randomized to DU 4.5 mg achieved A1C <7% in every baseline A1C category (A1C<8%, 75%, 87%, 83%; A1C 8-<9%, 61%, 64%, 73%; A1C 9-<10%, 46%, 51%, 64%; A1C ≥10%, 19%, 33%, 55% for DU 1.5 mg, 3 mg, and 4.5 mg, respectively; interaction p=0.096).
3 context sentences(design, population, supporting numbers)
Summary · context
More patients randomized to 3 mg or 4.5 mg achieved A1C <7% versus those on 1.5 mg at 36 weeks regardless of baseline A1C, but the difference across dose groups was greater at higher baseline A1Cs.
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812424
24HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C 9 to below 10%, 64% reached A1C below 7% with dulaglutide 4.5 mg versus 46% with 1.5 mg.
In plain wordsMore patients with initial A1C 9 to below 10% reached A1C below 7% with dulaglutide 4.5 mg than with 1.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseA1C target with baseline 9 to below 10%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
Patients achieving A1C <7%
64%
dulaglutide 4.5 mg, baseline A1C 9-<10%, 36 weeks
Patients achieving A1C <7%
46%
dulaglutide 1.5 mg, baseline A1C 9-<10%, 36 weeks
Source sentences
Summary
Over half of patients randomized to DU 4.5 mg achieved A1C <7% in every baseline A1C category (A1C<8%, 75%, 87%, 83%; A1C 8-<9%, 61%, 64%, 73%; A1C 9-<10%, 46%, 51%, 64%; A1C ≥10%, 19%, 33%, 55% for DU 1.5 mg, 3 mg, and 4.5 mg, respectively; interaction p=0.096).
3 context sentences(design, population, supporting numbers)
Summary · context
More patients randomized to 3 mg or 4.5 mg achieved A1C <7% versus those on 1.5 mg at 36 weeks regardless of baseline A1C, but the difference across dose groups was greater at higher baseline A1Cs.
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812425
25HumanRandomized controlled trialEfficacy outcome
In patients with baseline A1C at least 10%, 55% reached A1C below 7% with dulaglutide 4.5 mg versus 19% with 1.5 mg.
In plain wordsMore patients with initial A1C at least 10% reached A1C below 7% with dulaglutide 4.5 mg than with 1.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseA1C target with baseline at least 10%
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4.5 mg weekly · 36 weeksAs given in this study (human).
Measurements
Patients achieving A1C <7%
55%
dulaglutide 4.5 mg, baseline A1C ≥10%, 36 weeks
Patients achieving A1C <7%
19%
dulaglutide 1.5 mg, baseline A1C ≥10%, 36 weeks
Source sentences
Summary
Over half of patients randomized to DU 4.5 mg achieved A1C <7% in every baseline A1C category (A1C<8%, 75%, 87%, 83%; A1C 8-<9%, 61%, 64%, 73%; A1C 9-<10%, 46%, 51%, 64%; A1C ≥10%, 19%, 33%, 55% for DU 1.5 mg, 3 mg, and 4.5 mg, respectively; interaction p=0.096).
3 context sentences(design, population, supporting numbers)
Summary · context
More patients randomized to 3 mg or 4.5 mg achieved A1C <7% versus those on 1.5 mg at 36 weeks regardless of baseline A1C, but the difference across dose groups was greater at higher baseline A1Cs.
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812426
26HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dose-related A1C improvements across baseline categories persisted at 52 weeks with dulaglutide.
In plain wordsHigher dulaglutide doses maintained greater A1C improvement than 1.5 mg across initial A1C categories in patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDose response at 52 weeks
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 or 4.5 mg weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
Similar patterns of dose-related improvement in A1C and proportions of patients achieving A1C <7% across baseline A1C categories were observed at 52 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
A1C reductions were greater in patients randomized to DU 3 mg or 4.5 mg versus 1.5 mg in each A1C subgroup, with greater dose-related improvements in patients with higher baseline A1C through 36 weeks
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812427
27HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dose-related improvements in A1C target attainment across baseline categories persisted at 52 weeks with dulaglutide.
In plain wordsHigher dulaglutide doses maintained greater A1C target attainment than 1.5 mg across initial A1C categories in patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseA1C target dose response at 52 weeks
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 or 4.5 mg weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
Similar patterns of dose-related improvement in A1C and proportions of patients achieving A1C <7% across baseline A1C categories were observed at 52 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
More patients randomized to 3 mg or 4.5 mg achieved A1C <7% versus those on 1.5 mg at 36 weeks regardless of baseline A1C, but the difference across dose groups was greater at higher baseline A1Cs.
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
Report a problemFND-9067812428

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

28HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In patients with diabetes receiving dulaglutide, gastrointestinal adverse events were similar across baseline A1C subgroups.
In plain wordsDigestive adverse events were similar across initial A1C groups in patients with diabetes receiving dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeGastrointestinal adverse events by baseline A1C
Study
n: not reported in source
Comparator
Other baseline A1C subgroups
Analysis
Exploratory
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal adverse events were similar between A1C subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to once weekly DU 1.5 mg (n=612), 3 mg (n=616), or 4.5 mg (n=614).
Summary · context
All patients initiated once weekly DU 0.75 mg for 4 weeks, followed by stepwise dose escalation every 4 weeks to the randomized dose.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9067812429

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Abstract

PepBank is a research reference. Talk to a doctor before you use any peptide.